Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
December 7, 2019
Xenon Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
December 6, 2019
Xenon to Present at the 31st Annual Piper Jaffray Healthcare Conference
December 3, 2019
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
December 2, 2019
Xenon to Participate in Upcoming Investor Conferences
November 15, 2019
Xenon Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 5, 2019
Product Pipeline
* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
